Watch RAPH. Know when insiders buy.
One email the day a filing lands. Free.
RAPH
Raphael Pharmaceutical Inc.
1.40
+0.00 +0.00%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $28.2MP/E 28.0DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$980KNET CASH —52W 0.22 – 1.40SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$199K | −$223K | — | 0.01 | $0 | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$223K | −$229K | — | 0.01 | −$44K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$254K | −$273K | — | 0.02 | $46K | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$251K | −$255K | — | 0.01 | −$17K | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$315K | −$322K | — | 0.02 | −$30K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$425K | −$429K | — | 0.02 | −$209K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$394K | −$395K | −737.1% | 0.02 | −$62K | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$319K | −$326K | — | 0.01 | −$80K | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$249K | −$248K | — | 0.01 | −$218K | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$547K | −$550K | — | 0.03 | −$172K | $1K | −$173K | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | $74K | $62K | — | -0.01 | −$88K | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$729K | −$725K | — | 0.04 | −$501K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$1.2M | −$1.3M | — | 0.07 | −$210K | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$1.5M | −$1.5M | — | 0.08 | −$532K | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$1.3M | −$1.3M | — | 0.08 | −$1.2M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$3.3M | −$3.4M | — | 0.23 | −$759K | $2K | −$761K | — | — |
| FY2021 · to Dec 31 | — | — | −$1.6M | −$1.6M | — | 0.15 | −$1.4M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$706K | −$718K | — | 0.07 | −$779K | — | — | — | — |
Every number comes from Raphael Pharmaceutical Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.